Compare SPSC & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPSC | HCM |
|---|---|---|
| Founded | 1987 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.3B |
| IPO Year | 2009 | 2015 |
| Metric | SPSC | HCM |
|---|---|---|
| Price | $82.97 | $13.27 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 12 | 12 |
| Target Price | ★ $81.55 | $20.59 |
| AVG Volume (30 Days) | ★ 440.8K | 37.8K |
| Earning Date | 10-29-2026 | 07-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 20.59 | N/A |
| EPS | ★ 1.56 | N/A |
| Revenue | ★ $220,566,000.00 | N/A |
| Revenue This Year | $5.21 | $14.24 |
| Revenue Next Year | $6.26 | $11.52 |
| P/E Ratio | $118.07 | ★ $5.49 |
| Revenue Growth | ★ 14.11 | N/A |
| 52 Week Low | $49.04 | $9.77 |
| 52 Week High | $96.54 | $16.33 |
| Indicator | SPSC | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 43.10 | 42.06 |
| Support Level | $78.54 | $13.00 |
| Resistance Level | $85.31 | $15.10 |
| Average True Range (ATR) | 3.20 | 0.36 |
| MACD | -0.61 | -0.13 |
| Stochastic Oscillator | 11.63 | 7.14 |
SPS Commerce Inc is a provider of cloud-based supply chain management services for retailers, grocers, distributors, suppliers, and logistics firms to increase supply chain performance, optimize inventory levels and sell-through, reduce operational costs, improve order visibility, and satisfy consumer demands for a seamless omnichannel experience. Its solutions are delivered through the SPS Commerce platform and provide integrations and retail performance analytics to its customers. The company has one operating segment Supply Chain Management Solutions, that derives revenues from customers by providing access to cloud-based supply chain management services, primarily under subscription-based service arrangements.
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.